AI-Generated Filing Summaries

Director Daniel Schurr resigned from the CHS Board effective March 30, 2026, creating a vacancy.

Schurr's resignation was due to accepting a board seat at Nationwide Mutual Insurance Company.

Schurr had served on the CHS Board since 2006 and was Chair from 2017 to December 2025.

Director Daniel Schurr resigned from the CHS Board effective March 30, 2026, creating a vacancy.

Schurr's resignation was due to accepting a board seat at Nationwide Mutual Insurance Company.

Schurr had served on the CHS Board since 2006 and was Chair from 2017 to December 2025.

Director Daniel Schurr resigned from the CHS Board effective March 30, 2026, creating a vacancy.

Schurr's resignation was due to accepting a board seat at Nationwide Mutual Insurance Company.

Schurr had served on the CHS Board since 2006 and was Chair from 2017 to December 2025.

The company failed to comply with a minimum EBITDA financial covenant for the trailing three-month period ended March 31, 2026.

This failure constitutes an event of default under the Loan and Security Agreement with Gibraltar Business Capital, LLC.

The lender may declare all obligations immediately due and payable, which totaled approximately $6.5 million as of March 31, 2026.

T3 Defense Inc. terminated $16,000,000 obligation to wholly-owned subsidiary Star 26 Capital Inc.

Cancellation effective immediately under Cancellation Agreement dated March 31, 2026.

No cost, no dilution, and no offsetting obligations to Company or shareholders.

CEO Vinayak Hegde outlines a strategic focus on maximizing long-term intrinsic value through Economic Profit, AI enablement, and a Founder's Mentality.

GAAP net income per diluted share for 2025 was $36.38, an 83.0% increase from 2024, with a return on equity of 25.9%.

Adjusted net income per diluted share for 2025 was $40.95, a 5.2% increase, driven largely by a 6.6% decrease in weighted average diluted shares outstanding from share repurchases.

Vertro, Inc. — a wholly-owned subsidiary of Inuvo, Inc. — entered into an Extension Amendment to its Google Services Agreement on March 31, 2026.

The Amendment extends the Agreement’s term by three months, moving the expiration date from April 1, 2026 to June 30, 2026.

The Amendment introduces new definitions related to AdSense for Search Restricted Access Features (RAFs) and modifies compliance and implementation obligations.

Operating income and net income were both -$31.8K for Q3 FY2026, reflecting zero revenue and continued general and administrative spending as the Company remains in pre-commercial development.

Diluted EPS was $0.01 for Q3 FY2026 — a nominal positive value derived from GAAP reporting conventions despite an underlying net loss, underscoring the absence of revenue-generating operations.

Net cash used in operating activities totaled $68,707 for the nine months ended February 28, 2026, aligning with management’s stated focus on scaling infrastructure and preparing for market introduction.

Consumer Loan Marketplace Volume reached $1,190M in March 2026, +102% YoY, and $2,902M in Q1 2026, +113% YoY.

$YLDS In Circulation grew to $598M end of Q1 2026, +83% from Q4 2025.

Democratized Prime Matched Offers Balance at $368M, +79% QoQ; Borrower Demand $376M, +53% QoQ; Available Lender Supply $453M, +112% QoQ.

Revenue increased 5.4% to $2.5B from $2.4B in Q1 FY2025, reflecting volume gains in select verticals despite declines elsewhere.

Gross profit declined slightly to $849.7M from $855.9M, contracting gross margin to 34.0% primarily from cost of revenue pressures.

Operating income fell 29.8% to $118.6M from $168.9M as operating margin decreased to 4.7%, driven by lower gross margins and SG&A rising as a percentage of revenue.

Revenue increased 51.5% year-over-year to $5.126 million in FY2025, driven by expansion in Middle East markets and growth in e-Invoice and RPA businesses.

Net loss narrowed to $120,273 from $161,968 in FY2024, reflecting improved operational execution despite continued investment in AI-enhanced RPA.

Operating cash flow surged to $503,858 (from $24,401), indicating stronger collection efficiency and working capital management.

Shareholders approved 2025 annual accounts and total dividend of EUR 0.50 per A-share (EUR 0.20 per B-share).

Interim dividend of EUR 0.25 per A-share already paid on October 16, 2025; final dividend payable April 16, 2026.

Number of directors set at nine; re-elected Frank Esser (3-year term) and Anne-Catherine Ries (1-year term).

Bloomia Holdings expects gross proceeds of approximately $12.1 million from its rights offering, comprising $5 million in cash and $7.1 million from debt conversion.

Approximately 3 million shares of common stock will be issued to rights offering participants at a price of $4.05 per share.

The company intends to use net cash proceeds primarily to repay acquisition debt at a greater than 50% discount.

Audit Committee dismissed Deloitte effective April 1, 2026, and appointed RSM US LLP for fiscal year ending December 31, 2026.

Deloitte's audit reports for fiscal years 2024 and 2025 contained no adverse opinions, qualifications, or modifications.

No disagreements with Deloitte on accounting principles, disclosures, or audit scope through April 1, 2026.

The company entered into the Fifth Amendment to its WF Credit Agreement, waiving the Debt Service Coverage Ratio and Leverage Ratio requirements until May 31, 2026, or an unrelated Event of Default.

The company also entered into the Second Amendment to its KL Credit Agreement, waiving the same financial covenants for the period from January 1, 2026, through the fiscal quarter ending on or prior to March 31, 2026.

Both amendments require the company to refinance the credit facilities and repay all obligations within 60 days if the pending merger with Stanley Martin Homes, LLC does not close by May 31, 2026.

Stephen Ruffini, CFO since 2009, notified the Company on March 30, 2026 of his intent to transition from the CFO role as part of succession planning.

Ruffini will continue as CFO until a permanent replacement is appointed and then shift to a newly created executive role leading mergers and acquisitions.

The transition is not due to any dispute or disagreement with the Company regarding financial disclosures, accounting, operations, or policies.

Dividend of $625 per share declared on 10% Series A Cumulative Perpetual Preferred Stock — reflects contractual obligation and capital return commitment.

$0.625 dividend per Depositary Share (ALTG PRA) — aligns with the 1/1000th fractional interest structure and NYSE listing.

Record date is April 15, 2026 and payment date is April 30, 2026 — establishes clear timeline for eligible holders and cash outflow.

Dividend of $625 per share declared on 10% Series A Cumulative Perpetual Preferred Stock — reflects contractual obligation and capital return commitment.

$0.625 dividend per Depositary Share (ALTG PRA) — aligns with the 1/1000th fractional interest structure and NYSE listing.

Record date is April 15, 2026 and payment date is April 30, 2026 — establishes clear timeline for eligible holders and cash outflow.

Executive team will attend Kempen Life Sciences Conference for investor meetings.

Conference dates are April 15–16, 2026, located in Amsterdam, Netherlands.

Format is one-on-one investor meetings; no presentation is explicitly disclosed.

Executive team will attend Kempen Life Sciences Conference for investor meetings.

Conference dates are April 15–16, 2026, located in Amsterdam, Netherlands.

Format is one-on-one investor meetings; no presentation is explicitly disclosed.

The Advisory Agreement with Ashford Inc. is extended for ten years, from January 24, 2027 to January 24, 2037.

The extension was initiated by the Advisor via a written notice delivered on March 31, 2026.

All existing terms and conditions of the agreement remain in effect during the extended term.

The Advisory Agreement with Ashford Inc. is extended for ten years, from January 24, 2027 to January 24, 2037.

The extension was initiated by the Advisor via a written notice delivered on March 31, 2026.

All existing terms and conditions of the agreement remain in effect during the extended term.

The Advisory Agreement with Ashford Inc. is extended for ten years, from January 24, 2027 to January 24, 2037.

The extension was initiated by the Advisor via a written notice delivered on March 31, 2026.

All existing terms and conditions of the agreement remain in effect during the extended term.

Signed contract for construction of eight MR product tankers at Hyundai Heavy Industries.

Total purchase price approximately USD 405 million.

Deliveries expected between Q3 2028 and Q2 2029.

OSR Holdings will provide a $30M development financing facility to Vaximm AG for VXM01 clinical development.

BCM Europe AG will pay up to $815M in milestones directly to OSR Holdings upon clinical and regulatory achievements.

The agreement grants BCM Europe exclusive worldwide rights to VXM01 for all indications.

OSR Holdings will provide a $30M development financing facility to Vaximm AG for VXM01 clinical development.

BCM Europe AG will pay up to $815M in milestones directly to OSR Holdings upon clinical and regulatory achievements.

The agreement grants BCM Europe exclusive worldwide rights to VXM01 for all indications.

The Loan Agreement, originally dated November 7, 2024 and amended April 16, 2025, was terminated by mutual consent.

Neither the Borrower nor the Lender has any further obligations under the terminated agreement.

The termination became effective at 11:59 p.m. Eastern time on March 27, 2026.

Issued 1,267,767.846 common shares on March 31, 2026, for $24,990,239.78.

Issued 495.141 common shares on April 1, 2026, for $9,760.22.

Sales made under subscription agreements with investors funding capital commitments on drawdown notice.

Company raised aggregate gross proceeds of US$1,000,000 through a private placement transaction.

Issued 1,139,472 Class A ordinary shares at a price of $0.8776 per share.

Shares issued represent 23.24% of the Company's issued and outstanding Class A ordinary shares.

Board declared a $0.50 per share dividend on Series C Preferred Shares (NYSE: SB.PR.C).

Board declared a $0.50 per share dividend on Series D Preferred Shares (NYSE: SB.PR.D).

Dividends cover the period from January 30, 2026 to April 29, 2026.